Metabolic disease is a risk factor for developing dementia, and symptom progression in dementia has been slowed with drugs potentiating insulin signaling in rodents and in humans (Gudala et al. 2013; Moreira 2012; Bobsin and Kreienkamp 2015; Cooper et al. 2015; Bomfim et al. 2012; De Felice et al. 2009; Escribano et al. 2010; Querfurth and LaFerla 2010). Here, INS is linked to dementia.